Themis Bioscience, a Vienna, Austria-based biotechnology start-up developing vaccines to prevent infectious diseases, has completed a €5m Series A financing round.
The round was co-led by Ventech and Crédit Agricole Private Equity.
The company intends to use the funds to advance the pre-‐clinical and clinical development activities for its lead product
candidates, a Dengue and a Chikungunya Fever vaccine, which are both based on a novel vaccine vector technology (Themaxyn™) that was initially developed at the Institut Pasteur in Paris.
Founded in 2009 and led by CEO Erich Tauber, Themis Bioscience received seed financing by the academic business incubator INiTS, the austria wirtschaftsservice (aws) and The Austrian Research Promotion Agency (FFG).